Business Description
TME Pharma N.V. is a German drug development company working to bring new treatments to cancer patients. Its primary focus is NOX-A12, a drug currently being tested in combination with other therapies for difficult-to-treat cancers including pancreatic cancer, colorectal cancer, and brain tumors. Founded in 1997 and based in Berlin, the company was previously called NOXXON Pharma before adopting its current name in 2022.
